Navigation Links
Eisai/Pfizer's Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimer's Disease
Date:2/4/2008

Physician Familiarity and its Better Side-Effect/Safety Profile are Driving

Aricept Prescription Rates, According to a New Report from Decision

Resources

WALTHAM, Mass., Feb. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Eisai/Pfizer's Aricept owns a dominating 42.4% patient share for first-line treatment of newly diagnosed Alzheimer's disease patients. The new report entitled Treatment Algorithms in Alzheimer's Disease finds that the reasons for favoring Aricept differ between primary care physicians and neurologists. Primary care physicians prefer Aricept over other acetylcholinesterase inhibitors (AChEIs) largely because of their familiarity with the agent, while neurologists cite Aricept's side-effect/safety profile and easier titration (the dosing schedule needed for a patient to receive full therapeutic doses of a drug).

The report finds that, in first-line treatment, Aricept holds a 42.4% patient share. The two twice-per-day AChEIs -- Novartis's Exelon and Shire/Janssen/Ortho-McNeil's Razadyne hold only 2.8% and 1.4% shares, respectively. Aricept's first-line patient share also far exceeds that of the newer formulations of those two drugs, including the once-daily formulation of Razadyne, Razadyne ER.

"Aricept's critical attribute of once-daily administration was unique until the launch of Razadyne ER in 2005," said Madhuri Borde, Ph.D., analyst at Decision Resources. "However, our survey revealed that physicians prescribe Aricept more than any other AChEI, in large part because of their comfort level with the drug, and because primary care physicians have been slow to move to Razadyne ER."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to p
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
2. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
5. Breakthrough Opportunity for Improving Patient Health
6. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
7. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
8. Difficult to Treat Erectile Dysfunction Patients
9. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
10. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
11. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... 2015 goals, other key objectives, and financial guidance.  ... today at 4:30 p.m. EST to review the ... To participate in today,s call by telephone, please ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 On behalf ... its affiliated companies, Wilentz, Goldman & Spitzer, P.A. ... trade secrets lawsuit against Genewiz Inc. in excess of ... and utilized GenScript’s trade secrets, and that it improperly ... court entered an order denying motions for judgment notwithstanding ...
(Date:2/26/2015)... Already well respected for accuracy, HEIDENHAIN now ... Length Gauge offerings with new variants of its successful ... HEIDENHAIN’s pencil probe-style SPECTO length gauge series now offers ... 1Vpp, 12mm stroke length variants of the SPECTO series ... variant with a weak spring, 0.4N of gauging force, ...
(Date:2/26/2015)... Regis Technologies announced new potent ... drug substances. , Regis Technologies is proud to announce ... Compound Suite (PCS) for 2015. , Regis is a ... facility in Morton Grove, Illinois. The PCS addition will ... up to about one kilogram per batch. , ...
Breaking Biology Technology:Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Regis Extends cGMP Services to Oncology Market 2
... -- Four Oak Ridge National Laboratory researchers are among ... as part of the Department of Energy,s new Early ... under the American Recovery and Reinvestment Act by the ... researchers during the crucial early career years, when many ...
... , , SCOTTSDALE, Ariz. , ... of the delivery of modern-day cancer care in community oncology ... costs of administering chemotherapy and providing related infusion room services ... services provided such as treatment planning, care coordination, and follow-up ...
... Fourth Quarter and Year End 2009 Financial Results , VANCOUVER , ... ANP) will host a conference call discussing its financial results for the ... Thursday, March 4, 2010 at 9:00 AM ET ( ... March 4, 2010 is as follows: , North America ...
Cached Biology Technology:4 ORNL researchers selected for Recovery Act early career funds 24 ORNL researchers selected for Recovery Act early career funds 3Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer 2Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer 3Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer 4Angiotech Pharmaceuticals Announces Conference Call and Webcast 2
(Date:1/22/2015)...  Today, FreeWavz ( www.FreeWavz.com ), the developer of ... Fundable, https://www.fundable.com/freewavz . FreeWavz will be expanding ... meet customer demand. Logo - ... Invented by Dr. Eric ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
(Date:1/22/2015)... Issued by Small Cap IR. In 2011, Nilson Report,s annual ... merchants on the leading payment cards rose to $135.3 billion ... prepaid cards reached 6.54 billion.  Eight million credit card users ... 2012, and credit and debit card fraud resulted in $11.27 ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... neuroscientists at Oregon Health & Science University Doernbecher Children,s ... strength MRI to reveal tiny white matter injuries in ... Early, accurate identification of these lesions in the ... enable physicians to inform families sooner of the potential ...
... of 22 young European scientists selected for excellence in ... scientists join a growing network of more than 300 ... have the potential to be tomorrow,s life science leaders," ... the Young Investigator Programme. "They are already active contributors ...
... and physics aims to understand the cell and how ... very complicated. LMU biophysicist Professor Erwin Frey, who is ... Initiative Munich" (NIM) is working with his group on ... professor for statistical and biological physics and his team, ...
Cached Biology News:First use of high-field MRI in developing brain reveals previously undetectable injuries 222 young researchers join the 2011 EMBO Young Investigator Program 2Attention! End of traffic jam! 2
Peptide-affinity Purified Polyclonal Antibody to ICEBERG Peptide with sequence EEDPQLASKMGLH, from C Terminus of the protein sequence according to NP_067546...
EDG-6 Lysate Source: Cell Lysate Application: Western Blotting Control Form: IgG...
3T3 cells (RSV-transformed) Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Madin-Darby bovine kidney (MDBK) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Biology Products: